A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00943553 |
|
Recruitment Status :
Withdrawn
(Terminated by Sponsor)
First Posted : July 22, 2009
Last Update Posted : April 13, 2015
|
Sponsor:
Eisai Inc.
Information provided by (Responsible Party):
Eisai Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Actual Primary Completion Date : | August 2011 |
| Study Completion Date : | No date given |